Fusion Antibodies are delighted to be attending this year’s Bio Integrates conference taking place on 16th May 2023 in London. This one-day conference provides a unique forum to discuss the major challenges impacting the biotech, start-up and emerging pharma sector.

Our CEO Dr Adrian Kinkaid will be attending this event as a panel representative, alongside our Alliance Director Brett Whitecross and Ryan Tough, R&D Partnerships Manager who are attending as delegates.

If you would like to set up a meeting to discuss our capabilities or to find out more about how we can advance your project to the next stage, please contact us here.

About Fusion Antibodies

Fusion Antibodies is a contract research organisation, which designs, and optimizes therapeutic antibodies for the healthcare market. We help clients solve complex, challenging problems throughout their early discovery antibody programs. Our expertise is defined by our experience. Unique process frameworks, and technology platforms, enable our clients to develop therapeutics within the most challenging modalities and diseases. Guiding clients through early-stage antibody discovery, in the most efficient and effective way, we enable biotechnology and pharmaceutical organizations towards their end-goal – the provision of treatments that improve the lives of patients worldwide.